DISCOVER: How to Potentially Multiply Your Returns by Upto 5x...
Here is the latest financial fact sheet of Torrent Pharma. For more details, see the Torrent Pharma quarterly results and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -0.6 |
No. of shares | m | 169.26 |
% ch week | % | 0.8 |
% ch 1-mth | % | -7.4 |
% ch 12-mth | % | 13.5 |
52 week H/L | Rs | 3,040.0/1,619.0 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
TORRENT PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,232 | 1,720 | 1,768 | 1,550 | 1,964 | |
Low | Rs | 523 | 1,134 | 1,186 | 1,144 | 1,245 | |
Sales per share (Unadj.) | Rs | 275.0 | 394.5 | 346.1 | 351.6 | 453.4 | |
Earnings per share (Unadj.) | Rs | 44.4 | 102.4 | 55.2 | 40.1 | 25.8 | |
Diluted earnings per share | Rs | 44.4 | 102.4 | 55.2 | 40.1 | 25.8 | |
Cash flow per share (Unadj.) | Rs | 55.6 | 116.5 | 73.3 | 64.2 | 62.3 | |
Dividends per share (Unadj.) | Rs | 11.25 | 40.00 | 14.00 | 14.00 | 17.00 | |
Adj. dividends per share | Rs | 11.25 | 39.99 | 14.00 | 14.00 | 17.00 | |
Dividend yield (eoy) | % | 1.3 | 2.8 | 0.9 | 1.0 | 1.1 | |
Book value per share (Unadj.) | Rs | 156.2 | 206.5 | 257.1 | 273.1 | 279.2 | |
Adj. book value per share | Rs | 156.1 | 206.4 | 257.0 | 273.1 | 279.1 | |
Shares outstanding (eoy) | m | 169.22 | 169.22 | 169.22 | 169.22 | 169.22 | |
Bonus/Rights/Conversions | - | - | - | - | - | ||
Price / Sales ratio | x | 3.2 | 3.6 | 4.3 | 3.8 | 3.5 | |
Avg P/E ratio | x | 19.8 | 13.9 | 26.8 | 33.6 | 62.2 | |
P/CF ratio (eoy) | x | 15.8 | 12.3 | 20.1 | 21.0 | 25.8 | |
Price / Book Value ratio | x | 5.6 | 6.9 | 5.7 | 4.9 | 5.7 | |
Dividend payout | % | 25.4 | 39.1 | 25.4 | 34.9 | 65.9 | |
Avg Mkt Cap | Rs m | 148,465 | 241,435 | 249,887 | 227,897 | 271,513 | |
No. of employees | `000 | 11.0 | 10.9 | 11.8 | 14.7 | 13.6 | |
Total wages/salary | Rs m | 8,418 | 8,424 | 9,934 | 11,353 | 14,038 | |
Avg. sales/employee | Rs Th | 4,212.4 | 6,129.6 | 4,971.5 | 4,047.5 | 5,642.6 | |
Avg. wages/employee | Rs Th | 762.0 | 773.4 | 843.2 | 772.3 | 1,032.4 | |
Avg. net profit/employee | Rs Th | 679.8 | 1,591.3 | 792.4 | 461.3 | 320.9 |
TORRENT PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 46,535 | 66,764 | 58,569 | 59,498 | 76,728 | |
Other income | Rs m | 2,856 | 2,256 | 2,233 | 2,988 | 571 | |
Total revenues | Rs m | 49,390 | 69,020 | 60,802 | 62,487 | 77,299 | |
Gross profit | Rs m | 10,202 | 27,330 | 13,773 | 13,493 | 19,831 | |
Depreciation | Rs m | 1,907 | 2,376 | 3,069 | 4,086 | 6,177 | |
Interest | Rs m | 1,752 | 1,840 | 2,056 | 3,085 | 5,038 | |
Profit before tax | Rs m | 9,398 | 25,371 | 10,881 | 9,310 | 9,187 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | -1,936 | 0 | 0 | -3,570 | |
Tax | Rs m | 1,888 | 6,102 | 1,545 | 2,529 | 1,254 | |
Profit after tax | Rs m | 7,509 | 17,333 | 9,336 | 6,781 | 4,363 | |
Gross profit margin | % | 21.9 | 40.9 | 23.5 | 22.7 | 25.8 | |
Effective tax rate | % | 20.1 | 24.1 | 14.2 | 27.2 | 13.6 | |
Net profit margin | % | 16.1 | 26.0 | 15.9 | 11.4 | 5.7 |
TORRENT PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 40,983 | 46,882 | 48,794 | 52,623 | 50,375 | |
Current liabilities | Rs m | 27,046 | 32,855 | 27,383 | 52,022 | 51,653 | |
Net working cap to sales | % | 30.0 | 21.0 | 36.6 | 1.0 | -1.7 | |
Current ratio | x | 1.5 | 1.4 | 1.8 | 1.0 | 1.0 | |
Inventory Days | Days | 84 | 74 | 97 | 121 | 92 | |
Debtors Days | Days | 125 | 79 | 59 | 77 | 68 | |
Net fixed assets | Rs m | 34,720 | 39,007 | 42,079 | 85,016 | 83,648 | |
Share capital | Rs m | 846 | 846 | 846 | 846 | 846 | |
"Free" reserves | Rs m | 25,583 | 34,095 | 42,655 | 45,376 | 46,397 | |
Net worth | Rs m | 26,430 | 34,941 | 43,501 | 46,222 | 47,244 | |
Long term debt | Rs m | 21,729 | 18,501 | 22,408 | 41,115 | 39,129 | |
Total assets | Rs m | 79,641 | 90,579 | 97,021 | 142,432 | 141,209 | |
Interest coverage | x | 6.4 | 14.8 | 6.3 | 4.0 | 2.8 | |
Debt to equity ratio | x | 0.8 | 0.5 | 0.5 | 0.9 | 0.8 | |
Sales to assets ratio | x | 0.6 | 0.7 | 0.6 | 0.4 | 0.5 | |
Return on assets | % | 11.6 | 21.2 | 11.7 | 6.9 | 6.7 | |
Return on equity | % | 28.4 | 49.6 | 21.5 | 14.7 | 9.2 | |
Return on capital | % | 23.2 | 47.3 | 19.6 | 14.2 | 12.3 | |
Exports to sales | % | 30.4 | 43.3 | 0 | 0 | 0 | |
Imports to sales | % | 6.0 | 6.9 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 14,136 | 28,934 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 2,801 | 4,584 | 0 | 0 | 0 | |
Fx inflow | Rs m | 14,265 | 29,185 | 20,066 | 14,580 | 22,103 | |
Fx outflow | Rs m | 5,184 | 6,021 | 5,304 | 3,600 | 5,522 | |
Net fx | Rs m | 9,081 | 23,165 | 14,762 | 10,980 | 16,581 |
TORRENT PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 8,102 | 27,421 | 10,088 | 8,942 | 17,981 | |
From Investments | Rs m | -21,623 | -8,379 | -7,869 | -47,070 | -2,413 | |
From Financial Activity | Rs m | 12,123 | -14,352 | -1,929 | 34,174 | -13,145 | |
Net Cashflow | Rs m | -1,399 | 4,375 | 177 | -3,655 | 2,380 |
Share Holding
|
Company Information
|
CHM: Sudhir Mehta | COMP SEC: Mahesh Agarwal | YEAR OF INC: 1973 | BSE CODE: 500420 | FV (Rs): 5 | DIV YIELD (%): 0.7 |
More Pharmaceuticals Company Fact Sheets: PFIZER NEULAND LABS FULFORD INDIA STRIDES PHARMA SCIENCE NATCO PHARMA
Compare TORRENT PHARMA With: PFIZER NEULAND LABS FULFORD INDIA STRIDES PHARMA SCIENCE NATCO PHARMA
Compare TORRENT PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling during closing hours today and ended their day lower.
For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this video, I'll show you how to allocate your capital as a day trader.
More